Scancell Holdings plc

AIM:SCLP Stock Report

Market Cap: UK£115.2m

Scancell Holdings Future Growth

Future criteria checks 0/6

Scancell Holdings's revenue is forecast to decline at 55.3% per annum while its annual earnings are expected to grow at 0.3% per year. EPS is expected to decline by 17.7% per annum.

Key information

0.3%

Earnings growth rate

-17.70%

EPS growth rate

Biotechs earnings growth9.9%
Revenue growth rate-55.3%
Future return on equityn/a
Analyst coverage

Low

Last updated22 Jun 2026

Recent future growth updates

Recent updates

New Narrative • Jul 26

Phase III Funding Delays And Cash Burn Will Test Long-Term Cancer Immunotherapy Potential

Catalysts About Scancell Holdings Scancell Holdings is a biotechnology company focused on developing cancer immunotherapies and antibody programs across melanoma and other solid tumours. What are the underlying business or industry changes driving this perspective?
Narrative Update • Jul 26

SCLP: Fast Track Status And Nasdaq Path Will Support Bullish Outlook

Analysts have lowered their fair value estimate for Scancell Holdings from £0.31 to £0.26, citing updated assumptions around discount rates, revenue trends, profit margins, and a very large forward P/E multiple. What’s in the News for Scancell Holdings Scancell Holdings has completed a follow on equity offering of £13 million, issuing 144,444,444 ordinary shares at £0.09 per share, under Regulation S with a subsequent direct listing.
Analysis Article • Oct 29

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Feb 10

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Dec 28

Here's What Scancell Holdings plc's (LON:SCLP) Shareholder Ownership Structure Looks Like

Every investor in Scancell Holdings plc ( LON:SCLP ) should be aware of the most powerful shareholder groups...

Earnings and Revenue Growth Forecasts

AIM:SCLP - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
4/30/20272-8-15-51
4/30/20261-19-12-142
10/31/20255-6-10-9N/A
7/31/20255-9-9-8N/A
4/30/20255-12-8-6N/A
1/31/20252-14-11-10N/A
10/31/2024N/A-16-14-14N/A
7/31/2024N/A-11-15-15N/A
4/30/2024N/A-6-16-16N/A
1/31/2024N/A-8-13-13N/A
10/31/2023N/A-10-11-11N/A
7/31/20233-11-9-9N/A
4/30/20235-12-8-8N/A
1/31/20235-12-9-9N/A
10/31/20225-13-11-10N/A
7/31/20223-9-11-10N/A
4/30/2022N/A-5-11-10N/A
1/31/2022N/A-6-11-10N/A
10/31/2021N/A-8-11-9N/A
7/31/2021N/A-12-10-8N/A
4/30/2021N/A-15-9-8N/A
1/31/2021N/A-11-7-7N/A
10/31/2020N/A-7-6-5N/A
7/31/2020N/A-6-5-5N/A
4/30/2020N/A-6-5-5N/A
1/31/2020N/A-5-5-5N/A
10/31/2019N/A-5-6-6N/A
7/31/2019N/A-5N/A-6N/A
4/30/2019N/A-6N/A-7N/A
1/31/2019N/A-6N/A-6N/A
10/31/2018N/A-5N/A-6N/A
7/31/2018N/A-5N/A-5N/A
4/30/2018N/A-4N/A-4N/A
1/31/2018N/A-4N/A-4N/A
10/31/2017N/A-4N/A-4N/A
7/31/2017N/A-4N/A-4N/A
4/30/2017N/A-4N/A-4N/A
1/31/2017N/A-3N/A-3N/A
10/31/2016N/A-3N/A-3N/A
7/31/2016N/A-3N/A-3N/A
4/30/2016N/A-3N/A-2N/A
1/31/2016N/A-2N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SCLP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SCLP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SCLP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SCLP's revenue is expected to decline over the next 3 years (-55.3% per year).

High Growth Revenue: SCLP's revenue is forecast to decline over the next 3 years (-55.3% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SCLP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/19 17:57
End of Day Share Price 2026/08/19 00:00
Earnings2025/10/31
Annual Earnings2025/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Scancell Holdings plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julie SimmondsPanmure Liberum
James OrsborneStifel, Equities Research
Lala GregorekTrinity Delta Research Limited